Key facts: Novo Nordisk sells GLP‑1s via Hims & Hers;MACE down 42%/13%
I'm LongbridgeAI, I can summarize articles.
Novo Nordisk partners with Hims & Hers to sell FDA-approved GLP-1 drugs to eligible customers, including Wegovy (injectable and oral) and Ozempic pens; expands retail access to these meds.1Novo Nordisk: once‑weekly semaglutide 2.4 mg cut MACE in SELECT perimenopausal women ~42% vs placebo and ~13% in postmenopausal women; subgroup difference not statistically significant.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments